Loading…
Trial eligibility change
| eligibility_criteria | Key Inclusion Criteria: 1\. Advanced non-small cell lung cancer (aNSCLC) (defined as stage IIIB/C or stage IV) treated with cemiplimab in combination with platinum-doublet chemotherapy in the 1L setting from Nov 2022 to Jun 2026 as described in the protocol Key Exclusion Criteria: 1. Patients who have EGFR, ALK or ROS1 variants 2. Treatment with EGFR, ALK or ROS1 inhibitors at any time prior to the index date 3. Patients actively enrolled in a clinical trial in which they receive treatment with cemiplimab in combination with platinum-doublet chemotherapy Note: Other protocol-defined Inclusion/ Exclusion Criteria apply | → | Key Inclusion Criteria: 1\. Advanced non-small cell lung cancer (aNSCLC) (defined as stage IIIB/C or stage IV) treated with cemiplimab in combination with platinum-doublet chemotherapy in the 1L setting from Nov 2022 to Jun 2026 as described in the protocol Key Exclusion Criteria: 1. Participants who have EGFR, ALK or ROS1 variants 2. Treatment with EGFR, ALK or ROS1 inhibitors at any time prior to the index date 3. Participants actively enrolled in a clinical trial in which they receive treatment with cemiplimab in combination with platinum-doublet chemotherapy Note: Other protocol-defined Inclusion/ Exclusion Criteria apply |
Not scored.No materiality record exists yet for this event.
No other named entities identified.This event has no scored competitor read-through.
No real valuation-relevant phase transition on a resolved asset for this event.This section fires only when the event carries a resolved asset and a real phase change — not guessed for every event.